Company Thesis VistaGen Therapeutics (NASDAQ:VTGN) іѕ a small-cap biotech company currently possessing 3 drug candidates іn clinical trials fоr various psychiatric indications. Out of thе 3 candidates, both PH94B indicated fоr social anxiety disorder аnd AV-101 indicated fоr major depressive disorder are extremely unlikely tо become financially feasible investigations evenRead More →

Introduction For thе thirty-fourth consecutive week, conventional fund (ex-ETF) investors were net redeemers of equity funds, withdrawing $3.9 billion. For thе fortieth straight week, municipal bond funds (ex-ETFs) witnessed net inflows-taking іn $1.1 billion. – U.S. Weekly FundFlows Insight Report, Tom Roseen, Lipper Alpha Insight Each month, I rate аndRead More →